Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4721460 | 0.89 | TLR8 (0.31) | TLR8TLR7SMN1; SMN2 | |
| SCHEMBL4723833 | 0.81 | TLR8 (0.38) | TLR8TLR7SMN1; SMN2 | |
| SCHEMBL4724150 | 0.69 | POLB (0.33) | — | |
| SCHEMBL8847833 | 0.68 | — | — | |
| SCHEMBL4723368 | 0.66 | SMN1; SMN2 (0.35) | KDM4EALDH1A1HPGDTLR8TLR7 | |
| SCHEMBL5110106 | 0.66 | TLR8 (0.32) | TLR8TLR7SMN1; SMN2SLC29A1 | |
| SCHEMBL501043 | 0.65 | — | — | |
| SCHEMBL8847428 | 0.64 | — | — | |
| SCHEMBL4722311 | 0.63 | TLR8 (0.34) | ALDH1A1TLR8TLR7SMN1; SMN2SLC29A1 | |
| SCHEMBL4723460 | 0.63 | TLR8 (0.40) | KDM4EALDH1A1TLR8SMN1; SMN2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | KDM4E 2584/4885ALDH1A1 622/4885HPGD 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.